H. Miles Prince

28.1k total citations · 3 hit papers
428 papers, 14.8k citations indexed

About

H. Miles Prince is a scholar working on Oncology, Hematology and Pathology and Forensic Medicine. According to data from OpenAlex, H. Miles Prince has authored 428 papers receiving a total of 14.8k indexed citations (citations by other indexed papers that have themselves been cited), including 183 papers in Oncology, 141 papers in Hematology and 139 papers in Pathology and Forensic Medicine. Recurrent topics in H. Miles Prince's work include Lymphoma Diagnosis and Treatment (128 papers), Cutaneous lymphoproliferative disorders research (89 papers) and Multiple Myeloma Research and Treatments (85 papers). H. Miles Prince is often cited by papers focused on Lymphoma Diagnosis and Treatment (128 papers), Cutaneous lymphoproliferative disorders research (89 papers) and Multiple Myeloma Research and Treatments (85 papers). H. Miles Prince collaborates with scholars based in Australia, United States and Spain. H. Miles Prince's co-authors include Simon J. Harrison, John F. Seymour, David Ritchie, Ricky W. Johnstone, Mark Bishton, Michael Dickinson, Christopher McCormack, Paul J. Neeson, Stephen Lade and Andrew Spencer and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and Journal of Clinical Oncology.

In The Last Decade

H. Miles Prince

405 papers receiving 14.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Lenalidomide plus Dexamethasone for Relapsed or Refractory Multiple Myeloma

2007 1.1k citations Andrew Spencer, H. Miles Prince et al. profile →
Phase II Multi-Institutional Trial of the Histone Deacetylase Inhibitor Romidepsin As Monotherapy for Patients With Cutaneous T-Cell Lymphoma

2009 561 citations H. Miles Prince, Stephen Lade et al. Journal of Clinical Oncology profile →
Results From a Pivotal, Open-Label, Phase II Study of Romidepsin in Relapsed or Refractory Peripheral T-Cell Lymphoma After Prior Systemic Therapy

2012 485 citations Bertrand Coiffier, Barbara Pro et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by H. Miles Prince

Since Specialization

Citations

This map shows the geographic impact of H. Miles Prince's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by H. Miles Prince with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites H. Miles Prince more than expected).

Fields of papers citing papers by H. Miles Prince

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by H. Miles Prince. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by H. Miles Prince. The network helps show where H. Miles Prince may publish in the future.

Co-authorship network of co-authors of H. Miles Prince

This figure shows the co-authorship network connecting the top 25 collaborators of H. Miles Prince. A scholar is included among the top collaborators of H. Miles Prince based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with H. Miles Prince. H. Miles Prince is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Integrative analysis of the tumour immune microenvironment of breast implant-associated anaplastic large cell lymphoma using multi-omics 2025 ·Blood ·Criselle D’Souza, Niko Thio, (unknown), Heshani Desilva, Piers Blombery, Ella R. Thompson, Anand K. Deva, H. Miles Prince, Paul J. Neeson	0
2	A multicenter, phase Ib study of subcutaneous administration of isatuximab in combination with pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma 2024 ·Haematologica ·Hang Quach, Gurdeep Parmar, Enrique M. Ocio, H. Miles Prince, Albert Oriol, Helen Crowther, Nobuhiro Tsukada, Pierre Bories, Sumit Madan, Nitya Nathwani, Kazutaka Sunami, Dorothée Sémiond, (unknown), Paúl Cordero, Sandrine Macé, Florence Suzan, Philippe Moreau	2
3	Results from the First Phase 1 Clinical Study of DR-01, a Non-Fucosylated Anti-CD94 Targeting Antibody in Patients with Relapsed/Refractory Cytotoxic Lymphomas: Dose Escalation and Optimization 2024 ·Blood ·Jasmine M. Zain, Swaminathan P. Iyer, Enrica Marchi, Mitul Gandhi, Youn H. Kim, Michael S. Khodadoust, Jonathan E. Brammer, Christina Poh, Pierluigi Porcu, Kimberley Dilley, (unknown), (unknown), (unknown), (unknown), H. Miles Prince, Sarah McCue Horwitz	3
4	Geospatial analyses demonstrate variation of cutaneous T-cell lymphomas across Australia, providing insights into possible causes 2024 ·British Journal of Dermatology ·Belinda A. Campbell, Peter D. Baade, Paramita Dasgupta, (unknown), Sandro Porceddu, H. Miles Prince, Karin Thursky	1
5	Dynamics of Complete Responses in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma Treated with Odronextamab in the ELM-2 Study 2024 ·Blood ·Sabarish Ayyappan, H. Miles Prince, Cecilia Carpio, Isidro Jarque, Srikanth Ambati, (unknown), Hesham Mohamed, Giovanni Antico, (unknown), Jan Walewski	0
6	288: Mycosis Fungoides with Large Cell Transformation: Radiotherapy Dose Response and Patient Outcomes 2024 ·Radiotherapy and Oncology ·(unknown), (unknown), H. Miles Prince, Stephen Lade, Michael Fahey, Christopher McCormack, Carrie van der Weyden, (unknown), (unknown), (unknown), Belinda A. Campbell	1
7	International study of treatment efficacy in SS shows superiority of combination therapy and heterogeneity of treatment strategies 2023 ·Blood Advances ·Belinda A. Campbell, Gábor Dobos, (unknown), H. Miles Prince, M. Bagot, Felicity Evison, Carrie van der Weyden, Chris McCormack, Caroline Ram‐Wolff, (unknown), Julia Scarisbrick	19
8	BASELINE HEPATITIS B VACCINATION AND ANTI HBS LEVEL AMONG HEALTHCARE WORKERS IN A NEWLY COMMISSIONED GOVERNMENT DEDICATED ONCOLOGY HOSPITAL 2023 ·International Journal of Infectious Diseases ·(unknown), H. Miles Prince, Radha K. Dhiman	0
9	The importance of frailty assessment in multiple myeloma: a position statement from the Myeloma Scientific Advisory Group to Myeloma Australia 2023 ·Internal Medicine Journal ·(unknown), Anna Kalff, (unknown), Peter Mollee, P. Joy Ho, Simon J. Harrison, Simon Gibbs, H. Miles Prince, Andrew Spencer, Douglas Joshua, Cindy Lee, Silvia Ling, Nick Murphy, Ferenc Szabó, Jeff Szer, N Weber, Christopher Wård, Dipti Talaulikar, Andrew C.W. Zannettino, Hang Quach	6
10	Diagnosis, management and follow up of peripheral T‐cell lymphomas: a consensus practice statement from the Australasian Lymphoma Alliance 2021 ·Internal Medicine Journal ·Greg Hapgood, Maya Latimer, Sze Ting Lee, Bryone J. Kuss, Stephen Lade, Joshua W.D. Tobin, Duncan Purtill, Belinda A. Campbell, H. Miles Prince, Eliza A. Hawkes, Jake Shortt, Dejan Radeski	0
11	Chimeric antigen receptor T cells form nonclassical and potent immune synapses driving rapid cytotoxicity 2018 ·Proceedings of the National Academy of Sciences ·Alexander J. Davenport, Ryan Cross, Katherine A. Watson, Yi‐Han Liao, Wei Shi, H. Miles Prince, Paul A. Beavis, Joseph A. Trapani, Michael H. Kershaw, David Ritchie, Phillip K. Darcy, Paul J. Neeson, Misty R. Jenkins	244
12	Enumeration, functional responses and cytotoxic capacity of MAIT cells in newly diagnosed and relapsed multiple myeloma 2018 ·Scientific Reports ·Nicholas A. Gherardin, Liyen Loh, (unknown), Alexander J. Davenport, (unknown), (unknown), Phillip K. Darcy, Misty R. Jenkins, H. Miles Prince, Simon J. Harrison, Hang Quach, David P. Fairlie, Katherine Kedzierska, James McCluskey, Adam P. Uldrich, Paul J. Neeson, David Ritchie, Dale I. Godfrey	77
13	Dual-specific Chimeric Antigen Receptor T Cells and an Indirect Vaccine Eradicate a Variety of Large Solid Tumors in an Immunocompetent, Self-antigen Setting 2016 ·Clinical Cancer Research ·Clare Y. Slaney, Bianca von Scheidt, Alexander J. Davenport, Paul A. Beavis, Jennifer A. Westwood, Sherly Mardiana, David C. Tscharke, Sarah Ellis, H. Miles Prince, Joseph A. Trapani, Ricky W. Johnstone, Mark J. Smyth, Michele W.L. Teng, (unknown), Zhiya Yu, Steven A. Rosenberg, Nicholas P. Restifo, Paul J. Neeson, Phillip K. Darcy, Michael H. Kershaw	89
14	CAR-T Cells Inflict Sequential Killing of Multiple Tumor Target Cells 2015 ·Cancer Immunology Research ·Alexander J. Davenport, Misty R. Jenkins, Ryan Cross, Carmen S. Yong, H. Miles Prince, David Ritchie, Joseph A. Trapani, Michael H. Kershaw, Phillip K. Darcy, Paul J. Neeson	112
15	Results From a Pivotal, Open-Label, Phase II Study of Romidepsin in Relapsed or Refractory Peripheral T-Cell Lymphoma After Prior Systemic Therapy breakdown → 2012 ·Journal of Clinical Oncology ·Bertrand Coiffier, Barbara Pro, H. Miles Prince, Francine M. Foss, Lubomir Sokol, Matthew Greenwood, Dolores Caballero, Peter Borchmann, Franck Morschhauser, Martin Wilhelm, Lauren Pinter‐Brown, Swaminathan P. Iyer, Andrei R. Shustov, Jean Nichols, Susan Carroll, John Balser, Barbara Balser, Sarah McCue Horwitz	485
16	Phase III Placebo-Controlled Trial of Denileukin Diftitox for Patients With Cutaneous T-Cell Lymphoma 2010 ·Journal of Clinical Oncology ·H. Miles Prince, Madeleine Duvic, Ann Martin, Wolfram Sterry, Chalid Assaf, Yijun Sun, David J. Straus, Mark Acosta, A. Negro‐Vilar	152
17	Clinical and Immunohistochemical Features Associated with a Response to Bortezomib in Patients with Multiple Myeloma 2009 ·Clinical Cancer Research ·Mark A. Dawson, Stephen Opat, Yamna Taouk, Mark Donovan, (unknown), (unknown), Noemi Horvath, Andrew W. Roberts, H. Miles Prince, Mark Hertzberg, Catriona McLean, Andrew Spencer	25
18	FLUDARABINE BASED COMBINATION THERAPY IS HIGHLY ACTIVE AS PRIMARY OR SALVAGE TREATMENT IN PATIENTS WITH WALDENSTROM MACROGLOBULINEMIA 2009 ·Stefan Peinert, Constantine S. Tam, M Wolf, David Westerman, Henry Januszewicz, John D. Scarlett, H. Miles Prince, J.F. Seymour	1
19	Histone Deacetylase Inhibitor Panobinostat Induces Clinical Responses with Associated Alterations in Gene Expression Profiles in Cutaneous T-Cell Lymphoma 2008 ·Clinical Cancer Research ·Leigh Ellis, Yan Pan, Gordon K. Smyth, Daniel J. George, Chris McCormack, (unknown), Monica Mita, Joachim Beck, Howard A. Burris, Gail Ryan, Peter Atadja, Dale Butterfoss, Margaret Dugan, Kenneth W. Culver, Ricky W. Johnstone, H. Miles Prince	244
20	Prolonged Ciprofloxacin Administration Does Not Accelerate Neutrophil Recovery after Autologous Bone Marrow Transplantation 1996 ·Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy ·Jane Lu Hsu, H. Miles Prince, Kevin Imrie	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact